PTC Therapeutics Shares Fall ~$0.30 From Recent Highs As Traders Circulate Article From Regional Paper Highlighting 1 Man's Struggle With MS; Includes 'According to PTC, the FDA will notify the company by Tuesday whether or not ataluren has been approved'